Literature DB >> 21041740

Applying value-based insurance design to high-cost health services.

James C Robinson1.   

Abstract

Value-based insurance design programs have focused on reducing consumer cost sharing in health insurance for preventive tests and medications for chronic diseases. But for value-based design principles to have a stronger clinical and economic impact, they should be extended to expensive services and to those for which the evidence is limited or controversial. This paper proposes applying value-based insurance design principles to self-administered and office-administered specialty drugs, implantable medical devices, advanced imaging modalities, and major surgical procedures.

Entities:  

Mesh:

Year:  2010        PMID: 21041740     DOI: 10.1377/hlthaff.2010.0469

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Lots of enthusiasm, lots of questions.

Authors:  Michael D Dalzell
Journal:  Biotechnol Healthc       Date:  2011

Review 2.  Reasons for underutilization of bariatric surgery: The role of insurance benefit design.

Authors:  Hamlet Gasoyan; Gabriel Tajeu; Michael T Halpern; David B Sarwer
Journal:  Surg Obes Relat Dis       Date:  2018-10-13       Impact factor: 4.734

3.  Controlling health costs: physician responses to patient expectations for medical care.

Authors:  Amber K Sabbatini; Jon C Tilburt; Eric G Campbell; Robert D Sheeler; Jason S Egginton; Susan D Goold
Journal:  J Gen Intern Med       Date:  2014-05-29       Impact factor: 5.128

4.  Impact of payment reform on chemotherapy at the end of life.

Authors:  Carrie H Colla; Nancy E Morden; Jonathan S Skinner; J Russell Hoverman; Ellen Meara
Journal:  J Oncol Pract       Date:  2012-05       Impact factor: 3.840

5.  Impact of payment reform on chemotherapy at the end of life.

Authors:  Carrie H Colla; Nancy E Morden; Jonathan S Skinner; J Russell Hoverman; Ellen Meara
Journal:  Am J Manag Care       Date:  2012-05-01       Impact factor: 2.229

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.